The clinical mass spectrometry market is witnessing high growth owing to integration of omics technologies such as proteomics, metabolomics and lipidomics with mass spectrometry. Mass spectrometry based omics technologies help in identification of biomarkers for various diseases and thus play an important role in precision medicine approach. Another key trend contributing to the market growth is use of clinical mass spectrometry in pharmacokinetic/pharmacodynamic studies. It allows quantification of drugs and metabolites in biological samples and aids in understanding drug absorption, distribution, metabolism and excretion. This helps in optimization of dosage regimens
The global clinical mass spectrometry market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing demand for clinical mass spectrometry instruments from research laboratories and hospitals.
Regionally, North America accounted for largest share in the global clinical mass spectrometry market in 2022 and is projected to remain dominant during the forecast period. Increasing funding for research activities, presence of key market players, adoption of advanced mass spectrometry techniques are some factors attributed to its dominance. Asia Pacific region is expected to grow at fastest CAGR over the forecast period owing to rising healthcare expenditure, increasing research initiatives by pharmaceutical companies, and growing collaborations between industries and academic & research institutes.
Read More
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian